Does the media refer more to RYTM or QURE?

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Rhythm Pharmaceuticals' score of 0.61 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, QURE or LNTH?

Lantheus has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 117.05 -$198.97M -$3.48 N/A Lantheus $1.54B 4.23 $233.56M $4.15 24.16

Is QURE or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to uniQure's net margin of -1,154.42%. Lantheus' return on equity of 29.32% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Lantheus 18.05% 29.32% 15.00%

Does the media favor QURE or LNTH?

In the previous week, Lantheus had 3 more articles in the media than uniQure. MarketBeat recorded 5 mentions for Lantheus and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Lantheus' score of 0.44 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MIRM or QURE?

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $521.31M 10.77 -$23.36M -$13.61 N/A uniQure $16.10M 117.05 -$198.97M -$3.48 N/A

Does the media favor MIRM or QURE?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for uniQure. Mirum Pharmaceuticals' average media sentiment score of 1.08 beat uniQure's score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TGTX or QURE?

TG Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 9.96 $447.18M $2.86 14.02 uniQure $16.10M 117.05 -$198.97M -$3.48 N/A

Is TGTX or QURE more profitable?

TG Therapeutics has a net margin of 65.95% compared to uniQure's net margin of -1,154.42%. TG Therapeutics' return on equity of 88.73% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% uniQure -1,154.42% -145.81% -27.15%

Does the media refer more to TGTX or QURE?

In the previous week, TG Therapeutics had 11 more articles in the media than uniQure. MarketBeat recorded 13 mentions for TG Therapeutics and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat TG Therapeutics' score of 0.74 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QURE or CNTA?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for uniQure. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat uniQure's score of 0.99 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$29.88 +3.12 (+11.66%)

Closing price 04:00 PM Eastern

Extended Trading

$30.55 +0.67 (+2.24%)

As of 08:00 PM Eastern

Compare

QURE vs. RYTM, LNTH, MIRM, TGTX, and CNTA

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does uniQure compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Rhythm Pharmaceuticals has higher revenue and earnings than uniQure. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	30.59	-$196.54M	-$3.13	N/A
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A

78.8% of uniQure shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, uniQure has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than uniQure. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Rhythm Pharmaceuticals' score of 0.61 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals currently has a consensus target price of $131.81, indicating a potential upside of 55.60%. uniQure has a consensus target price of $42.83, indicating a potential upside of 43.35%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Rhythm Pharmaceuticals has a net margin of -93.33% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

Rhythm Pharmaceuticals beats uniQure on 11 of the 17 factors compared between the two stocks.

How does uniQure compare to Lantheus?

uniQure (NASDAQ:QURE) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

uniQure currently has a consensus price target of $42.83, suggesting a potential upside of 43.35%. Lantheus has a consensus price target of $101.86, suggesting a potential upside of 1.60%. Given uniQure's higher possible upside, equities research analysts clearly believe uniQure is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 3 more articles in the media than uniQure. MarketBeat recorded 5 mentions for Lantheus and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat Lantheus' score of 0.44 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 18.05% compared to uniQure's net margin of -1,154.42%. Lantheus' return on equity of 29.32% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.16

78.8% of uniQure shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Lantheus beats uniQure on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 2 mentions for uniQure. Mirum Pharmaceuticals' average media sentiment score of 1.08 beat uniQure's score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to uniQure's net margin of -1,154.42%. Mirum Pharmaceuticals' return on equity of -11.28% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
uniQure	-1,154.42%	-145.81%	-27.15%

Mirum Pharmaceuticals presently has a consensus target price of $137.64, indicating a potential upside of 49.56%. uniQure has a consensus target price of $42.83, indicating a potential upside of 43.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.77	-$23.36M	-$13.61	N/A
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

78.8% of uniQure shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats uniQure on 13 of the 17 factors compared between the two stocks.

How does uniQure compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

TG Therapeutics currently has a consensus price target of $52.50, indicating a potential upside of 30.89%. uniQure has a consensus price target of $42.83, indicating a potential upside of 43.35%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, TG Therapeutics had 11 more articles in the media than uniQure. MarketBeat recorded 13 mentions for TG Therapeutics and 2 mentions for uniQure. uniQure's average media sentiment score of 0.99 beat TG Therapeutics' score of 0.74 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.96	$447.18M	$2.86	14.02
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A

TG Therapeutics has a net margin of 65.95% compared to uniQure's net margin of -1,154.42%. TG Therapeutics' return on equity of 88.73% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

TG Therapeutics beats uniQure on 12 of the 17 factors compared between the two stocks.

How does uniQure compare to Centessa Pharmaceuticals?

uniQure (NASDAQ:QURE) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Centessa Pharmaceuticals has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Centessa Pharmaceuticals' return on equity of -60.37% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

78.8% of uniQure shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

uniQure presently has a consensus price target of $42.83, indicating a potential upside of 43.35%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 3.72%. Given uniQure's stronger consensus rating and higher possible upside, research analysts plainly believe uniQure is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has lower revenue, but higher earnings than uniQure. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	117.05	-$198.97M	-$3.48	N/A
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for uniQure. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat uniQure's score of 0.99 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Centessa Pharmaceuticals beats uniQure on 9 of the 16 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.69B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-8.59	9.91	18.89	22.53
Price / Sales	117.05	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	9.37	6.63	9.84	6.72
Net Income	-$198.97M	$24.20M	$3.57B	$337.19M
7 Day Performance	18.71%	-3.24%	-1.16%	0.48%
1 Month Performance	56.19%	0.53%	3.85%	5.07%
1 Year Performance	97.10%	47.24%	27.40%	34.25%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	3.4049 of 5 stars	$29.88 +11.7%	$42.83 +43.4%	+84.8%	$1.69B	$16.10M	N/A	500
RYTM Rhythm Pharmaceuticals	2.7558 of 5 stars	$87.84 -2.6%	$131.81 +50.1%	+32.5%	$6.18B	$189.76M	N/A	140	Analyst Forecast
LNTH Lantheus	2.4079 of 5 stars	$103.00 +9.0%	$99.71 -3.2%	+24.9%	$6.15B	$1.54B	24.82	1,193	Gap Down
MIRM Mirum Pharmaceuticals	3.738 of 5 stars	$98.62 -2.0%	$137.08 +39.0%	+100.5%	$6.14B	$521.31M	N/A	140	Positive News Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.8957 of 5 stars	$38.87 -0.9%	$52.50 +35.1%	+2.5%	$6.01B	$616.29M	13.59	290	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. RYTM, LNTH, MIRM, TGTX, and CNTA

How does uniQure compare to Rhythm Pharmaceuticals?

Summary

How does uniQure compare to Lantheus?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Summary

How does uniQure compare to TG Therapeutics?

Summary

How does uniQure compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. RYTM, LNTH, MIRM, TGTX, and CNTA

How does uniQure compare to Rhythm Pharmaceuticals?

Which has better earnings & valuation, RYTM or QURE?

Do insiders & institutionals have more ownership in RYTM or QURE?

Which has more risk and volatility, RYTM or QURE?

Does the media refer more to RYTM or QURE?

Do analysts recommend RYTM or QURE?

Is RYTM or QURE more profitable?

Summary

How does uniQure compare to Lantheus?

Do analysts recommend QURE or LNTH?

Which has more volatility and risk, QURE or LNTH?

Does the media favor QURE or LNTH?

Is QURE or LNTH more profitable?

Which has stronger earnings and valuation, QURE or LNTH?

Do institutionals and insiders hold more shares of QURE or LNTH?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Does the media favor MIRM or QURE?

Is MIRM or QURE more profitable?

Do analysts recommend MIRM or QURE?

Which has better valuation & earnings, MIRM or QURE?

Which has more risk and volatility, MIRM or QURE?

Do institutionals & insiders believe in MIRM or QURE?

Summary

How does uniQure compare to TG Therapeutics?

Do analysts prefer TGTX or QURE?

Which has more volatility and risk, TGTX or QURE?

Does the media refer more to TGTX or QURE?

Do institutionals and insiders believe in TGTX or QURE?

Which has higher earnings and valuation, TGTX or QURE?

Is TGTX or QURE more profitable?

Summary

How does uniQure compare to Centessa Pharmaceuticals?

Is QURE or CNTA more profitable?

Do insiders & institutionals have more ownership in QURE or CNTA?

Which has more volatility and risk, QURE or CNTA?

Do analysts rate QURE or CNTA?

Which has higher valuation and earnings, QURE or CNTA?

Does the media prefer QURE or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools